Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.91 -0.21%
Revenue Growth %: +37.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +37.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
